Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG: Aclidinium bromide
- DRUG: Other COPD medication
Sponsor
AstraZeneca
Collaborators